{"schema_version":"secwatch.filing_event.v1","accession":"0001714899-23-000103","form_type":"8-K","ticker":"DNLI","cik":"0001714899","company_name":"Denali Therapeutics Inc.","filed_at":"2023-06-20T23:59:59+00:00","discovered_at":"2026-05-14T18:03:40.180552+00:00","generated_at":"2026-06-13T21:28:07.452059+00:00","sec_items":["8.01","9.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.8,"calibrated_materiality_score":0.8,"confidence":"high","headline":"Denali reports 64% reduction in NfL with DNL310 in MPS II after 2 years","bullets":["Mean serum NfL reduction of 64% (p<0.001) from baseline at 2 years in Phase 1/2 study (n=13).","FDA recommended assessment of NfL as a possible biomarker in neuronopathic MPS II.","Additional interim data from Phase 1/2 to be presented at SSIEM symposium in August 2023.","Global Phase 2/3 COMPASS study of DNL310 ongoing; management hosted investor webinar June 20."],"urls":{"canonical":"https://secwatch.observer/filing/0001714899-23-000103","json":"https://secwatch.observer/filing/0001714899-23-000103.json","markdown":"https://secwatch.observer/filing/0001714899-23-000103.md","text":"https://secwatch.observer/filing/0001714899-23-000103.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1714899/000171489923000103/0001714899-23-000103-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1714899/000171489923000103/dnli-20230620.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-13T21:28:07.452059+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}